<DOC>
	<DOCNO>NCT00377962</DOCNO>
	<brief_summary>This study investigate whether initiation everolimus together reduction calcineurin inhibitor ( CNI ) maintenance heart lung transplant patient renal impairment would improve renal function .</brief_summary>
	<brief_title>Nordic Everolimus ( Certican ) Trial Heart Lung Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>Inclusion criterion : Patients undergone heart lung transplantation 12 month ago . Patients receive Neoral® Prograf® . Patients measure calculated glomerular filtration rate ( GFR ) &gt; 20 &lt; 70 mL/min/1.73m^2 . For patient GFR &gt; 60 &lt; 70 mL/min/1.73m^2 , deteriorate renal function since time transplantation must document least one posttransplant GFR level &gt; 10 % GFR level time inclusion . Patients willing capable give write informed consent study participation able participate study 12 month . Females potential childbearing age must negative serum pregnancy test within 7 day prior enrollment . Effective contraception must use trial 6 week follow discontinuation study medication , even history infertility . Exclusion criterion : Patients recipient multiple organ transplant . Patients measure GFR &lt; 20 mL/min/1.73m^2 &gt; 70 mL/min/1.73m^2 . Patients treat acute rejection episode within last 3 month . Patients platelet count &lt; 50,000/mm^3 white blood cell count ≤ 2,500/mm^3 hemoglobin value &lt; 8 g/dL . Presence severe hypercholesterolemia ( ≥ 8.0 mmol/L ) hypertriglyceridemia ( ≥ 6.0 mmol/L ) despite conventional lipid lower treatment . Patients currently treat treated mammalian target rapamycin ( mTOR ) inhibitor . Patients receive investigational drug within 4 week . Patients human immunodeficiency virus positive current severe systemic infection require continue therapy accord investigator judgment . Present use immunosuppressive drug Neoral®/Prograf® , mycophenolic acid/azathioprine ( MPA/AZA ) , and/or steroid . Patients know hypersensitivity drug similar everolimus . Symptoms significant mental illness , opinion investigator , may interfere patient 's ability comply protocol . History drug alcohol abuse within 1 year baseline . Inability cooperate communicate investigator . Patients past ( within last 5 year ) present malignancy excise squamous basal cell carcinoma . Females childbearing potential planning become pregnant , pregnant and/or lactating , unwilling use effective mean contraception . Patients plan coronary revascularization patient experience major adverse cardiovascular event ( MACE ) within last 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>thoracic transplant recipient</keyword>
	<keyword>everolimus</keyword>
	<keyword>immunosuppressant</keyword>
</DOC>